Dental researchers confirm microRNAs as biomarkers for oral cancer detection EurekAlert! Tue, 25 Aug 2009 14:01 PM PDT ( University of California - Los Angeles ) UCLA School of Dentistry researchers have substantiated the effectiveness of measuring the microRNAs in saliva to detect oral squamous cell carcinoma. Two particular microRNAs, miR-125a and miR-200a, are present at significantly different levels in the saliva of individuals suffering from OSCC. This latest finding offers another minimally invasive, ... | BC BREAKING NEWS : Kelowna Capital News Tue, 25 Aug 2009 14:00 PM PDT others also read... He has a monument at Mile Zero, an annual run for cancer research and Mount Terry Fox Provincial Park between the B.C.-Alberta border is named in his honour. | Prostate cancer hormone drugs risky for some men Deseret News Tue, 25 Aug 2009 13:57 PM PDT CHICAGO â" A new study links hormone therapy for prostate cancer with a higher risk of death in older men who've had serious heart problems. Hormone therapy suppresses the amount of testosterone produced, in turn causing prostate tumors to shrink or grow more slowly. | Petes go Pink The Peterborough Examiner Tue, 25 Aug 2009 13:48 PM PDT The Canadian Cancer Society is partnering with the Peterborough Petes to host a special game night Pink In The Rink Feb. 11, 2010. The partnership was announced at the Memorial Centre Tuesday and the Society has enlisted former Pete and NHLer Luke Richardson as honorary chairman.[...] | DFeet Breast Cancer event set for Oct. 24 Galveston County Daily News Tue, 25 Aug 2009 13:47 PM PDT GALVESTON The DFeet Breast Cancer Celebration of Life Run-Walk returns Oct. 24 at Moody Gardens in Galveston. | ORIGINAL CONTRIBUTION: Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery ... Journal of the American Medical Association Tue, 25 Aug 2009 13:43 PM PDT Context Hormonal therapy (HT) when added to radiation therapy (RT) for treating unfavorable-risk prostate cancer leads to an increase in survival except possibly in men with moderate to severe comorbidity. However, it is unknown which comorbid conditions eliminate this survival benefit. Objective To assess whether neoadjuvant HT use affects the risk of all-cause mortality in men with prostate ... | | |
|
No comments:
Post a Comment